AtriCure reports strong third-quarter results and raises 2026 guidance
+1 new source since this summary was written
AtriCure reported third-quarter revenue of $154.5M, up 15.1% year-over-year on a constant currency basis, with net income of $4.1M and adjusted EPS of 17 cents. The company raised its 2026 revenue outlook to $606M-$610M, adjusted EBITDA guidance to $91M-$94M from $85M-$89M, and adjusted EPS guidance to $0.40-$0.46 from $0.24-$0.32. BoxX-NoAF enrollment remains on track for completion before year-end, with over 880 patients enrolled and less than 100 remaining.
Why it matters
The higher outlook changes AtriCure's stated 2026 revenue, adjusted EBITDA and adjusted EPS ranges. BTIG raised its price target to $70 from $63 while maintaining a Buy rating after the results.
Key facts
- 1AtriCure reported third-quarter revenue of $154.5M and net income of $4.1M, compared with a loss in the prior year. finance.yahoo.com
- 2U.S. pain management revenue grew 34.6% to $28.1M in the quarter. finance.yahoo.com
- 3AtriCure raised its 2026 adjusted EBITDA guidance to $91M-$94M from $85M-$89M and its adjusted EPS guidance to $0.40-$0.46 from $0.24-$0.32. investing.com
- 4BoxX-NoAF had enrolled over 880 patients, with less than 100 patients needed to reach full enrollment. finance.yahoo.com
- 5BTIG increased its AtriCure price target to $70 from $63. investing.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.